$3.01 Billion is the total value of Avidity Partners Management LP's 83 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 35.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARVN | Sell | ARVINAS INC | $116,762,948 | -31.0% | 4,273,900 | -13.7% | 3.88% | +5.6% |
| ARGX | Sell | ARGENX SEsponsored adr | $104,583,206 | -55.8% | 280,700 | -55.1% | 3.47% | -32.3% |
| JAZZ | Sell | JAZZ PHARMACEUTICALS PLC | $99,197,107 | -14.4% | 677,900 | -6.8% | 3.29% | +31.1% |
| AKRO | Sell | AKERO THERAPEUTICS INC | $93,622,220 | -55.3% | 2,447,000 | -36.0% | 3.11% | -31.6% |
| RARE | Sell | ULTRAGENYX PHARMACEUTICAL IN | $85,288,690 | -38.4% | 2,126,900 | -28.9% | 2.83% | -5.7% |
| UHS | Sell | UNIVERSAL HLTH SVCS INCcl b | $85,157,000 | -26.8% | 670,000 | -18.8% | 2.83% | +12.2% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $82,565,154 | -61.2% | 815,700 | -54.2% | 2.74% | -40.5% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $81,635,136 | -45.3% | 3,865,300 | -34.1% | 2.71% | -16.1% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $57,337,280 | -58.1% | 416,000 | -60.6% | 1.90% | -35.8% |
| PRTA | Sell | PROTHENA CORP PLC | $51,775,654 | -70.9% | 1,068,200 | -63.8% | 1.72% | -55.4% |
| IDYA | Sell | IDEAYA BIOSCIENCES INC | $50,435,782 | -27.4% | 3,673,400 | -4.0% | 1.67% | +11.2% |
| ZNTL | Sell | ZENTALIS PHARMACEUTICALS INC | $50,383,960 | -51.4% | 2,929,300 | -43.1% | 1.67% | -25.6% |
| BSX | Sell | BOSTON SCIENTIFIC CORP | $42,525,500 | -71.8% | 850,000 | -73.9% | 1.41% | -56.7% |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $38,192,256 | -26.1% | 619,200 | -7.6% | 1.27% | +13.2% |
| IMCR | Sell | IMMUNOCORE HLDGS PLCads | $38,058,912 | -42.2% | 769,800 | -33.3% | 1.26% | -11.5% |
| BLU | Sell | BELLUS HEALTH INC NEW | $32,785,754 | -13.3% | 4,553,577 | -1.0% | 1.09% | +32.8% |
| ICLR | Sell | ICON PLC | $30,522,011 | -26.9% | 142,900 | -33.5% | 1.01% | +11.9% |
| RVMD | Sell | REVOLUTION MEDICINES INC | $29,128,368 | -50.6% | 1,344,800 | -45.7% | 0.97% | -24.3% |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $21,316,572 | -28.7% | 1,244,400 | -18.5% | 0.71% | +9.4% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $20,405,722 | -57.3% | 6,519,400 | -3.9% | 0.68% | -34.5% |
| Sell | BIOHAVEN LTD | $20,315,152 | -1.9% | 1,487,200 | -0.3% | 0.67% | +50.1% | |
| VERV | Sell | VERVE THERAPEUTICS INC | $19,491,514 | -35.6% | 1,351,700 | -13.6% | 0.65% | -1.4% |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $19,426,116 | -73.3% | 1,265,545 | -61.4% | 0.64% | -59.0% |
| PCVX | Sell | VAXCYTE INC | $19,114,800 | -75.3% | 510,000 | -68.4% | 0.63% | -62.2% |
| ARQT | Sell | ARCUTIS BIOTHERAPEUTICS INC | $17,913,500 | -31.0% | 1,628,500 | -7.2% | 0.60% | +5.7% |
| PNT | Sell | POINT BIOPHARMA GLOBAL INC | $17,532,332 | -1.1% | 2,411,600 | -0.9% | 0.58% | +51.6% |
| DXCM | Sell | DEXCOM INC | $17,194,640 | -79.9% | 148,000 | -80.4% | 0.57% | -69.3% |
| NTLA | Sell | INTELLIA THERAPEUTICS INC | $15,541,590 | -30.2% | 417,000 | -34.7% | 0.52% | +7.1% |
| Sell | CARIBOU BIOSCIENCES INC | $14,648,166 | -19.1% | 2,758,600 | -4.3% | 0.49% | +24.0% | |
| NTRA | Sell | NATERA INC | $13,874,448 | -80.8% | 249,900 | -86.1% | 0.46% | -70.5% |
| CYTK | Sell | CYTOKINETICS INC | $8,867,880 | -54.0% | 252,000 | -40.1% | 0.29% | -29.7% |
| ALPN | Sell | ALPINE IMMUNE SCIENCES INC | $7,638,940 | +1.1% | 989,500 | -3.8% | 0.25% | +54.9% |
| KNTE | Sell | KINNATE BIOPHARMA INC | $7,250,000 | -2.0% | 1,160,000 | -4.3% | 0.24% | +50.6% |
| Sell | AN2 THERAPEUTICS INC | $7,137,984 | +0.7% | 723,200 | -2.7% | 0.24% | +53.9% | |
| CMPX | Sell | COMPASS THERAPEUTICS INC | $5,967,750 | -40.7% | 1,825,000 | -8.8% | 0.20% | -9.2% |
| ALT | Sell | ALTIMMUNE INC | $5,550,144 | -91.5% | 1,315,200 | -67.0% | 0.18% | -87.1% |
| IPSC | Sell | CENTURY THERAPEUTICS INC | $4,400,307 | -34.2% | 1,268,100 | -2.7% | 0.15% | +0.7% |
| SGMO | Sell | SANGAMO THERAPEUTICS INC | $4,347,200 | -49.6% | 2,470,000 | -10.1% | 0.14% | -23.0% |
| CYT | Sell | CYTEIR THERAPEUTICS INC | $3,210,662 | +8.4% | 1,764,100 | -1.8% | 0.11% | +67.2% |
| BCAB | Sell | BIOATLA INC | $1,614,700 | -84.5% | 602,500 | -52.2% | 0.05% | -76.0% |
| Sell | REUNION NEUROSCIENCE INC | $104,318 | -79.3% | 151,098 | -73.0% | 0.00% | -72.7% | |
| MSACW | Exit | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $0 | – | -57,770 | -100.0% | 0.00% | – |
| ZLAB | Exit | ZAI LAB LTDadr | $0 | – | -31,309 | -100.0% | -0.02% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -104,653 | -100.0% | -0.02% | – |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -1,140,600 | -100.0% | -0.04% | – |
| DNAB | Exit | SOCIAL CAP SUVRETTA HLDS CRP | $0 | – | -200,000 | -100.0% | -0.04% | – |
| DNAD | Exit | SOCIAL CAP SUVRETTA HLDS CP | $0 | – | -200,000 | -100.0% | -0.04% | – |
| HSAQ | Exit | HEALTH SCIENCES ACQ CORP 2 | $0 | – | -400,000 | -100.0% | -0.09% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -1,855,400 | -100.0% | -0.10% | – |
| ARYD | Exit | ARYA SCIENCES ACQU CORP IVcl a | $0 | – | -500,000 | -100.0% | -0.11% | – |
| PANA | Exit | PANACEA ACQUISITION CORP II | $0 | – | -500,000 | -100.0% | -0.11% | – |
| MSAC | Exit | MEDICUS SCIENCES ACQUISITION | $0 | – | -520,000 | -100.0% | -0.11% | – |
| GRPH | Exit | GRAPHITE BIO INC | $0 | – | -1,575,000 | -100.0% | -0.11% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS IN | $0 | – | -1,126,000 | -100.0% | -0.40% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -204,000 | -100.0% | -0.49% | – |
| ITCI | Exit | INTRA-CELLULAR THERAPIES INC | $0 | – | -504,000 | -100.0% | -0.58% | – |
| BNTX | Exit | BIONTECH SEsponsored ads | $0 | – | -215,400 | -100.0% | -0.70% | – |
| DGX | Exit | QUEST DIAGNOSTICS INC | $0 | – | -258,000 | -100.0% | -0.87% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -172,000 | -100.0% | -1.08% | – |
| LLY | Exit | LILLY ELI & CO | $0 | – | -217,000 | -100.0% | -1.72% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -1,200,000 | -100.0% | -1.76% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -430,000 | -100.0% | -2.70% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -785,500 | -100.0% | -4.73% | – |
| XBI | Exit | SPDR SER TRcall | $0 | – | -4,062,000 | -100.0% | -7.30% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.